Introduction to The INTERCEPT Blood System Pathogen Reduction System
Pathogen reduction has been in routine use throughout Europe Since 2002. In 2014, the United States FDA approved the INTERCEPT Blood System for Platelets and Plasma Pathogen Reduction System. In this presentation, we will discuss the need for a proactive approach to blood safety, as well as introduce the INTERCEPT Blood System.
We will begin by reviewing the importance of blood safety and the challenges faced in protecting our blood supply. Current screening and testing measures have greatly improved blood safety. However, residual risks remain due to reliance on donor health and travel questionnaire responses, long test development, lead times limited testing sensitivity and window periods.
Routine testing exists for only a limited number of known pathogens, such as HIV and HCV. This still leaves gaps in the detection of new and emerging pathogens. Residual leukocytes can cause harmful post-transfusion reactions such as transfusion-associated-graft-versus-host-disease (TA-GVHD). Bacteria are the most frequently transfusion transmitted infections.